Showing results (81-90 of 94) with videos related to
Sort By:
Pageof 10
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11 beta-HSD1 inhibitorsDustin L McMinn, Yosup Rew, Athena Sudom, et al.Bioorganic & Medicinal Chemistry Letters|July 22, 2014
Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interactionYingcai Wang, Jiang Zhu, Jiwen Jim Liu, et al.Bioorganic & Medicinal Chemistry Letters|November 25, 2010
Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitorsDaqing Sun, Zhulun Wang, Seb Caille, et al.Journal of Medicinal Chemistry|September 1, 2020
Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine ProductionXiaohui Du, Jared Moore, Brian R Blank, et al.Journal of Medicinal Chemistry|June 17, 2008
Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo modelLisa D Julian, Zhulun Wang, Tracy Bostick, et al.ACS Medicinal Chemistry Letters|August 23, 2014
Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 InteractionMing Yu, Yingcai Wang, Jiang Zhu, et al.Journal of Medicinal Chemistry|November 19, 2019
Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or BioisostereGwenaella Rescourio, Ana Z Gonzalez, Salman Jabri, et al.Journal of Medicinal Chemistry|April 20, 2013
Rational design and binding mode duality of MDM2-p53 inhibitorsFelix Gonzalez-Lopez de Turiso, Daqing Sun, Yosup Rew, et al.Journal of Medicinal Chemistry|March 8, 2014
Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteresAna Z Gonzalez, Zhihong Li, Hilary P Beck, et al.Journal of Medicinal Chemistry|October 26, 2025
Discovery of ORIC-533, an Orally Bioavailable CD73 Inhibitor That Maintains Activity in High AMP Environments to Reverse Tumor ImmunosuppressionJared T Moore, Hiroyuki Kawai, Brian R Blank, et al.Pageof 10